Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;48(2):130-140.
doi: 10.1053/j.seminoncol.2021.04.001. Epub 2021 May 3.

Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual

Affiliations

Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual

Grace Clarke Hillyer et al. Semin Oncol. 2021 Apr.

Abstract

Participation in clinical trials is essential to bringing novel and innovative cancer treatments to the bedside but trials that specifically enroll Veterans are relatively few. Given the inherent differences between Veterans and the general United States population, we sought to investigate awareness of and attitudes toward clinical trials among Veterans diagnosed with cancer at a large, urban Veterans Administration Medical Center in Bronx, New York. The survey was administered in 2018-2019. Questions assessed sociodemographic characteristics, health literacy, and general attitudes about clinical trials. Based on key informant interviews, we also inquired about military-specific attitudes. Univariable analyses were conducted to evaluate differences in attitudes by age (<65 v ≥65 years) and race/ethnicity (non-Hispanic black v other). Of 115 Veterans approached, 67 (58.3%) completed the survey. Approximately 95% of participants were male, 59.7% were ≥65 years old, and 41.8% were non-Hispanic black. Only 58.2% reported knowing what a clinical trial is but 78.5% of Veterans stated that they trust doctors who do medical research and 87.5% reported they would strongly consider joining a trial if their VA primary care physician recommended it. Many stated that they would be part of a clinical trial if it would help fellow Veterans in the future (93.8%) and would help scientists learn how to treat other Veterans with the same disease (93.8%). Among non-Hispanic black participants, 62.5% agreed that the government has a history of using Veterans in experiments without their knowledge compared to 34.2% of Veterans of other race/ethnicity (P = 0.03). Clearly Veterans in our study were amenable to joining clinical trials. While many are aware of past misconduct in the treatment of military personnel in research, overall attitudes toward clinical trials were favorable and were especially positive when the possibility of improving cancer care for fellow Veterans was considered. In approaching Veterans regarding participation in a clinical trial we recommend education aligned with the literacy level of the Veteran, involvement of the VA primary care provider in clinical trial decisions, and awareness of a Veteran's altruism to help others.

Keywords: Attitudes; Cancer; Clinical trials; Military personnel; Survey; Veterans.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Overall positive, negative, and military-specific attitudes toward clinical trials among Veterans diagnosed with cancer at the Bronx Veterans Hospital (n = 67).

References

    1. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16(22):5557–63. - PMC - PubMed
    1. Carlisle B, Kimmelman J, Ramsay T, et al. Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clinical Trials 2015;12(1):77–83. - PMC - PubMed
    1. Khunger M, Rakshit S, Tullio K, et al. Premature clinical trial discontinuation in all and genitourinary (GU) cancers in the era of immune checkpoint inhibitors (ICI). J Clin Oncol 2017;35(6_suppl):394-. - PMC - PubMed
    1. Williams RJ, Tse T, DiPiazza K, et al. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination. PloS One 2015;10(5):e0127242–e. - PMC - PubMed
    1. Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI 2019;111(3):245–55. - PMC - PubMed

Publication types